The Iron Paradox on TRT: Why Blood Donation Can Backfire

You get your bloods back on TRT. Haematocrit is creeping past 52%. Your doctor tells you to donate blood. You do. Haematocrit drops. Problem solved, right?

Not quite. Each donation pulls 200-250 mg of iron out of your body. Meanwhile, the same testosterone that raised your haematocrit is suppressing hepcidin, the hormone that controls iron availability, forcing your body to burn through iron stores faster than you can replace them. A few donations later, your ferritin is in the single digits, your red blood cells are small and poorly formed, and new evidence suggests the phlebotomy itself may be increasing your clotting risk through a completely different pathway.

This is the iron paradox: TRT simultaneously raises your red blood cell count and depletes the iron you need to make those cells properly.

How testosterone rewires iron metabolism

To understand the paradox, you need to know what testosterone actually does to iron handling. There is not a single mechanism at work. Three coordinated changes redirect your body's entire iron supply toward red blood cell production.

Hepcidin: the gatekeeper testosterone disables

Hepcidin is a small peptide hormone produced by the liver that acts as the master regulator of iron metabolism. It controls ferroportin, the only known protein that exports iron from cells into the bloodstream. When hepcidin is high, ferroportin is degraded, and iron stays locked inside storage cells. When hepcidin falls, ferroportin remains active, and iron floods into circulation.

Testosterone suppresses hepcidin directly. Guo et al. (2013) showed that the androgen receptor physically binds to Smad1 and Smad4 proteins, preventing them from activating the hepcidin gene promoter in hepatocytes. This is not a downstream side effect of increased red blood cell production; it is a direct transcriptional suppression (Guo et al., 2013).

How fast does this happen? Within 7 days. Bachman et al. (2010) found that all dose groups (25 to 600 mg/week of testosterone enanthate) experienced at least a 50% drop in serum hepcidin within the first week. At high doses, hepcidin fell from roughly 87 ng/mL to 35 ng/mL, a 60% decline (Bachman et al., 2010).

Dhindsa et al. (2016) added another layer: testosterone not only suppresses hepcidin but also upregulates ferroportin expression by 70% and transferrin receptor expression by 43% in peripheral cells. The result is a coordinated iron channelling system. Every door that moves iron toward the bone marrow gets thrown open simultaneously (Dhindsa et al., 2016).

The new haemoglobin set point

Testosterone does not just stimulate a temporary burst of red blood cell production. It recalibrates the feedback loop between erythropoietin (EPO) and haemoglobin.

Bachman et al. (2014) tracked EPO and hepcidin over 6 months in men on testosterone. At 1 and 3 months, EPO was significantly elevated and hepcidin was suppressed. By 6 months, both had drifted back toward baseline, yet haemoglobin and haematocrit remained 7-10% above pre-treatment levels. The body had accepted a new normal: it no longer needed elevated EPO to maintain the higher haemoglobin because the entire set point had shifted upward (Bachman et al., 2014).

This explains why haematocrit stays elevated for as long as you are on testosterone. It is not a transient spike. Your body is defending a permanently higher target.

The dose-response is linear and predictable

Coviello et al. (2008) administered graded doses of testosterone enanthate (25, 50, 125, 300, and 600 mg/week) to 121 men over 20 weeks after suppressing endogenous production with a GnRH agonist. Haemoglobin and haematocrit increased in a linear, dose-dependent fashion (p < 0.0001). Older men (60-75) showed significantly greater responses than younger men (19-35) at every dose level (Coviello et al., 2008).

One more detail worth noting: Beggs et al. (2014) confirmed that blocking DHT conversion with finasteride did not reduce the erythropoietic effect. Hepcidin was still suppressed 57%, RBC count still rose 9%, and haematocrit still climbed 4%. If you are using finasteride for hair protection, do not expect it to protect you from erythrocytosis (Beggs et al., 2014).

The phlebotomy trap

The standard clinical advice for TRT-induced erythrocytosis is simple: donate blood, lower your haematocrit. Endocrine Society guidelines recommend dose reduction or phlebotomy when haematocrit exceeds 54%. Most TRT clinics and online communities treat blood donation as routine maintenance.

The problem is that this approach treats one number on a lab panel while potentially worsening the underlying biology.

The iron arithmetic

Each 500 mL whole blood donation removes approximately 210-240 mg of elemental iron and drops ferritin by roughly 30 ng/mL over the following month. Without supplementation, iron stores take a median of 168 days (about 24 weeks) to recover on a standard Western diet, which provides only 1-2 mg of absorbed iron per day (Mantadakis et al., 2022).

An athlete donating every 8 weeks, as many in the bodybuilding community do, is running a structural iron deficit. Three or four donations without supplementation can exhaust storage iron entirely. Meanwhile, testosterone-driven hepcidin suppression keeps demanding more iron for erythropoiesis. The supply cannot keep up with demand.

The HIF pathway problem

Here is where it gets worse. A 2024 review in Endocrine Connections by Bond, Verdegaal, and Smit made a provocative argument: phlebotomy for TRT-induced erythrocytosis may paradoxically increase thrombotic risk rather than reduce it (Bond et al., 2024).

The mechanism involves hypoxia-inducible factor (HIF). Prolyl hydroxylase domain (PHD) enzymes normally tag HIF-alpha for destruction, keeping it in check. These enzymes require iron as a cofactor. When iron stores are depleted by repeated phlebotomy, PHD enzymes cannot function properly, and HIF-alpha accumulates. Elevated HIF-alpha then upregulates prothrombotic genes, including tissue factor, P-selectin, thrombospondin-1, and PAI-1.

The Chuvash erythrocytosis model provides supporting evidence. In this congenital HIF-gain-of-function disorder, Shah et al. (2023) found that EPO elevation correlated with thrombosis more strongly than haematocrit level over 11 years of follow-up, and that iron depletion from phlebotomy may further elevate HIF activity (Shah et al., 2023). Bond et al. (2024) argue this supports the case that phlebotomy-driven iron depletion in TRT patients may increase thrombotic risk through the same HIF mechanism.

Iron-deficient erythrocytosis also creates a separate platelet-mediated risk: iron deficiency shifts progenitor cell commitment toward megakaryocyte production, increasing platelet counts and mean platelet volume, with roughly a 2-fold increased thrombosis risk independent of haematocrit.

When phlebotomy makes sense and when it does not

Used as a short-term bridge, phlebotomy is appropriate when haematocrit is above 54% and you have already decided to reduce your testosterone dose or change formulation. One or two donations bring haematocrit down while the dose reduction takes effect, and this is unlikely to cause meaningful iron depletion.

What does not work is using phlebotomy to maintain haematocrit below a target indefinitely, every 6-8 weeks, without changing the androgen dose. That creates cumulative iron depletion, chronic HIF-alpha elevation, sustained prothrombotic gene expression, and reactive thrombocytosis. You may be offsetting the very risk reduction you are trying to achieve.

Functional vs absolute iron deficiency

If you have been donating blood on TRT and your doctor checks your ferritin, the result might look reassuring. Ferritin of 120 ng/mL, well within the normal range. But you could still be functionally iron-deficient.

Why ferritin alone is unreliable

Ferritin is an acute-phase reactant. It rises with inflammation, liver stress, and infection, independently of iron stores. In non-inflammatory contexts, ferritin below 30 ug/L is a reliable marker for iron deficiency. But when inflammation is present, that threshold breaks down. Dignass et al. (2018) recommend using ferritin below 100 ug/L or transferrin saturation below 20% as the diagnostic threshold in inflammatory states (Dignass et al., 2018).

For athletes using oral AAS alongside testosterone, this matters. 17-alpha-alkylated compounds cause hepatic inflammation that elevates ferritin independently of iron stores. A user with liver stress can show ferritin of 200-400 ng/mL that reflects inflammation, not iron repletion, while genuine iron deficiency hides underneath.

The distinction that matters

Absolute iron deficiency means total body iron stores are depleted. Low ferritin, low TSAT, low serum iron, elevated TIBC, elevated sTfR. This is what happens after repeated phlebotomy without supplementation.

Functional iron deficiency means stores exist but cannot be mobilised fast enough for erythropoiesis. Ferritin may be normal or elevated, but TSAT is below 20% and sTfR is elevated. The bone marrow is iron-starved despite apparently adequate stores.

Both produce the same endpoint: red cell precursors that lack the iron they need. And both are missed if you only check ferritin.

The sTfR/log-ferritin index: gold standard for AAS users

Soluble transferrin receptor (sTfR) reflects what erythroid precursors are actually experiencing. When the bone marrow is iron-starved, transferrin receptor expression on red cell precursors increases, and the truncated extracellular domain accumulates in serum as sTfR. This is a direct readout of iron supply at the point of use, not storage.

The critical advantage: sTfR is not significantly affected by acute-phase reactions. Unlike ferritin, it does not rise with inflammation or liver stress, making it the most reliable single iron marker for AAS users (Margetic et al., 2005).

The sTfR/log-ferritin index combines both markers into a single ratio:

Index = sTfR (mg/L) / log10(ferritin ug/L)

Skikne et al. (2011) showed that ferritin alone detects only 41% of iron deficiency cases. Adding sTfR and the index raises detection to 92%. An index above 1.03 (Beckman assay) or above 2.06 (Roche assay) indicates iron-deficient erythropoiesis (Skikne et al., 2011).

The complete iron monitoring panel

If you are on TRT or running compounds, checking haematocrit alone is not enough. Here is the full panel, why each marker matters, and what to aim for.

When to test

• Baseline: Full panel before starting TRT or a cycle. This is your reference point.
• 3 months: The peak window for hepcidin suppression and erythropoietic drive. Catches problems early.
• 12 months: Confirms iron status has stabilised or identifies chronic depletion.
• Annually: Ongoing monitoring if stable.
• After phlebotomy: Recheck iron panel 6-8 weeks after each donation.

Injection protocol as a risk modifier

Not all testosterone formulations carry the same erythrocytosis risk. The pharmacokinetic profile, specifically the peak concentration and time spent above a hepcidin-suppressing threshold, matters more than total weekly dose.

Intramuscular enanthate/cypionate dosed every two weeks carries the highest risk. Erythrocytosis rates run from 40-67% depending on the study and threshold used. Large supraphysiological peaks in the first 24-72 hours drive the most aggressive hepcidin suppression (Ohlander et al., 2018).

Subcutaneous cypionate dosed daily or every other day produces lower peak-to-trough fluctuations and less acute hepcidin suppression. Around 12% erythrocytosis incidence in studies, substantially lower than biweekly IM dosing (Figueiredo et al., 2022).

Transdermal gels carry the lowest risk for most users. The TRAVERSE trial (n=5,246) reported fewer than 1% of gel users exceeding 54% haematocrit (Bond et al., 2024).

Intranasal testosterone (Natesto) has a roughly 40-minute half-life with three-times-daily dosing, and produced 0% erythrocytosis at the 54% threshold versus 10% for intramuscular cypionate in a head-to-head comparison (Best et al., 2021).

The practical implication: if erythrocytosis is your main concern on TRT, switching from biweekly IM injections to more frequent, smaller subcutaneous doses can meaningfully reduce your risk. You are smoothing out the peaks that drive hepcidin suppression.

For athletes on supraphysiological doses, this distinction still applies. Splitting a 500 mg/week dose into daily subcutaneous injections will produce lower peaks than a single weekly IM injection, though the absolute erythrocytosis risk at these doses remains high regardless of protocol.

The hemochromatosis wildcard

Everything discussed so far assumes testosterone depletes iron. But there is a scenario where TRT pushes iron in the opposite direction: undiagnosed hereditary hemochromatosis.

Hereditary hemochromatosis (HH) is far more common than most people realise. The highest-risk genotype (C282Y homozygous) affects about 0.5% of Northern European-descended populations. Compound heterozygotes (C282Y/H63D) make up roughly 2.4%, and about 10% carry at least one C282Y allele. H63D heterozygosity alone affects 23-37% of some populations.

Here is the clinical trap: hypogonadism is the most common endocrine complication of hemochromatosis. Iron deposits accumulate in the anterior pituitary, suppressing LH and FSH production. Prevalence of hypogonadism in HH ranges from 6.4% overall to 89% in those with cirrhosis (El Osta et al., 2017). A man presenting with low testosterone who is placed on TRT may have hemochromatosis as the root cause of his hypogonadism. TRT then treats the symptom while accelerating the underlying disease by further suppressing hepcidin and increasing iron absorption.

Schumacher and Gosmanov (2022) reported a case series where 4 of 5 patients who developed erythrocytosis on combined TRT and SGLT-2 inhibitor therapy carried H63D heterozygosity, a genotype typically considered low-risk. In combination with testosterone-induced hepcidin suppression, even a single HFE allele variant may be enough to produce clinically significant iron loading (Schumacher & Gosmanov, 2022).

Practical management

Iron supplementation: when and how

If your ferritin has dropped below 30-50 ng/mL from phlebotomy, supplementation is appropriate. The goal is restoring depleted stores without aggressively pushing haematocrit higher.

Iron bisglycinate is the preferred oral form. It is considered more bioavailable than ferrous sulfate, and a 2023 systematic review and meta-analysis of 17 RCTs found 64% fewer gastrointestinal side effects compared to other iron salts (Fischer et al., 2023). A dose of 18-25 mg elemental iron daily is reasonable for repletion without excessive erythropoietic stimulation.

IV iron (ferric carboxymaltose, ferumoxytol) is warranted when ferritin falls below 20-30 ng/mL with symptoms, when repeated phlebotomy renders oral repletion inadequate, or when GI intolerance prevents oral therapy. IV iron replenishes stores within 2-4 weeks versus 3-6 months for oral supplementation. This requires medical supervision.

Dietary factors that matter

Iron absorption is heavily influenced by what you eat alongside your supplement or iron-containing meal (Piskin et al., 2022).

Vitamin C (50-100 mg with your iron dose) counteracts absorption inhibitors, and heme iron from red meat absorbs 2-3x more efficiently than plant-based non-heme iron. On the inhibitor side: coffee and tea reduce absorption by 40-95% depending on tannin content, calcium supplements taken with iron are inhibitory, and red wine (polyphenols) significantly reduces absorption.

The practical rule: take your iron supplement with vitamin C, away from coffee, tea, and calcium. A two-hour window on either side is sufficient.

Decision framework

Key takeaways

• Testosterone suppresses hepcidin within 7 days, redirecting iron toward red blood cell production and raising haematocrit. This is a permanent recalibration, not a transient spike.
• Each blood donation removes 200-250 mg of iron. Frequent phlebotomy without supplementation creates iron-deficient erythrocytosis, a state where haematocrit stays high but red blood cells are poorly formed.
• 2024 evidence questions whether ongoing phlebotomy for TRT-induced erythrocytosis is safe. Iron depletion activates HIF pathways that may increase clotting risk independently of haematocrit.
• Ferritin alone is unreliable for AAS users. It is falsely elevated by liver inflammation and may miss functional iron deficiency. The sTfR/log-ferritin index is the gold standard.
• Track the full iron panel: ferritin, TSAT, serum iron, TIBC, sTfR, haemoglobin, haematocrit, and RBC. Baseline, 3 months, 12 months, then annually.
• Injection frequency matters. More frequent, smaller doses produce lower testosterone peaks and less hepcidin suppression than biweekly IM injections.
• If ferritin is persistently elevated above 200 ng/mL on TRT without liver inflammation, screen for HFE mutations.
• Iron bisglycinate (18-25 mg/day with vitamin C) is the preferred oral supplement for post-phlebotomy repletion, with fewer GI side effects than ferrous sulfate.

---

References

1. Bachman, E., Feng, R., Travison, T., Li, M., Olbina, G., Ostland, V., Ulloor, J., Zhang, A., Basaria, S., Ganz, T., Westerman, M., & Bhasin, S. (2010). Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. Journal of Clinical Endocrinology & Metabolism, 95(10), 4743-4747. PubMed

2. Bachman, E., Travison, T. G., Basaria, S., Davda, M. N., Guo, W., Li, M., Westfall, J. C., Bae, H., Gordeuk, V., & Bhasin, S. (2014). Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 69(6), 725-735. PubMed

3. Beggs, L. A., Yarrow, J. F., Conover, C. F., Meuleman, J. R., Beck, D. T., Morrow, M., Zou, B., Shuster, J. J., & Borst, S. E. (2014). Testosterone alters iron metabolism and stimulates red blood cell production independently of dihydrotestosterone. American Journal of Physiology: Endocrinology and Metabolism, 307(5), E456-461. PubMed

4. Best, J. C., Gonzalez, D., Masterson, T. A., Blachman-Braun, R., Pai, R., & Ramasamy, R. (2021). A cross-sectional comparison of secondary polycythemia in testosterone-deficient men treated with nasal testosterone gel vs. intramuscular testosterone cypionate. Canadian Urological Association Journal, 15(2), E118-E122. PubMed

5. Bond, P., Verdegaal, T., & Smit, D. L. (2024). Testosterone therapy-induced erythrocytosis: can phlebotomy be justified? Endocrine Connections, 13(10), e240283. PubMed

6. Coviello, A. D., Kaplan, B., Lakshman, K. M., Chen, T., Singh, A. B., & Bhasin, S. (2008). Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. Journal of Clinical Endocrinology & Metabolism, 93(3), 914-919. PubMed

7. Dhindsa, S., Ghanim, H., Batra, M., Kuhadiya, N. D., Abuaysheh, S., Green, K., Makdissi, A., Chaudhuri, A., & Dandona, P. (2016). Effect of testosterone on hepcidin, ferroportin, ferritin and iron binding capacity in patients with hypogonadotropic hypogonadism and type 2 diabetes. Clinical Endocrinology (Oxford), 85(5), 772-780. PubMed

8. Dignass, A., Farrag, K., & Stein, J. (2018). Limitations of serum ferritin in diagnosing iron deficiency in inflammatory conditions. International Journal of Chronic Diseases, 2018, 9394060. PubMed

9. El Osta, R., Grandpre, N., Monnin, N., Hubert, J., & Koscinski, I. (2017). Hypogonadotropic hypogonadism in men with hereditary hemochromatosis. Basic and Clinical Andrology, 27, 13. PubMed

10. Figueiredo, M. G., Gagliano-Juca, T., & Basaria, S. (2022). Testosterone therapy with subcutaneous injections: a safe, practical, and reasonable option. Journal of Clinical Endocrinology & Metabolism, 107(3), 614-626. PubMed

11. Guo, W., Bachman, E., Li, M., et al. (2013). Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging Cell, 12(2), 280-291. PubMed

12. Mantadakis, E., Panagopoulou, P., Kontekaki, E., Bezirgiannidou, Z., & Martinis, G. (2022). Iron deficiency and blood donation: links, risks and management. Journal of Blood Medicine, 13, 775-786. PubMed

13. Margetic, S., Topic, E., Ferenec Ruzic, D., & Kvaternik, M. (2005). Soluble transferrin receptor and transferrin receptor-ferritin index in iron deficiency anemia and anemia in rheumatoid arthritis. Clinical Chemistry and Laboratory Medicine, 43(3), 326-331. PubMed

14. Fischer, J. A. J., Cherian, A. M., Bone, J. N., & Karakochuk, C. D. (2023). The effects of oral ferrous bisglycinate supplementation on hemoglobin and ferritin concentrations in adults and children: a systematic review and meta-analysis of randomized controlled trials. Nutrition Reviews, 81(8), 904-920. PubMed

15. Ohlander, S. J., Varghese, B., & Pastuszak, A. W. (2018). Erythrocytosis following testosterone therapy. Sexual Medicine Reviews, 6(1), 77-85. PubMed

16. Piskin, E., Cianciosi, D., Gulec, S., Tomas, M., & Capanoglu, E. (2022). Iron absorption: factors, limitations, and improvement methods. ACS Omega, 7(24), 20441-20456. PubMed

17. Schumacher, K. A., & Gosmanov, A. R. (2022). Hemochromatosis gene mutation in persons developing erythrocytosis on combined testosterone and SGLT-2 inhibitor therapy. Journal of Investigative Medicine High Impact Case Reports, 10, 23247096221111774. PubMed

18. Shah, B. N., Zhang, X., Sergueeva, A. I., Miasnikova, G. Y., Ganz, T., Prchal, J. T., & Gordeuk, V. R. (2023). Increased transferrin protects from thrombosis in Chuvash erythrocytosis. American Journal of Hematology, 98(10), 1532-1539. PubMed

19. Skikne, B. S., Punnonen, K., Caldron, P. H., Bennett, M. T., Rehu, M., Gasior, G. H., Chamberlin, J. S., Sullivan, L. A., Bray, K. R., & Southwick, P. C. (2011). Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. American Journal of Hematology, 86(11), 923-927. PubMed